Articles related to BLADDER CANCER

This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.

Explore the nuanced implications of the FDA’s accelerated approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible urothelial carcinoma patients, including questions on optimal treatment duration and adverse effects.

Explore the latest findings from the VESPER trial that suggest a promising shift in bladder cancer treatment strategy, potentially setting a new standard for neoadjuvant therapy.

Discover a holistic perspective on advanced bladder and renal cell cancers management, encompassing everything from pathogenesis to adverse event mitigation. Let’s dive into the “Advanced Bladder and Renal Cell Cancers Management” webcast, released on April 30, 2023, offering valuable 1.00 ANCC contact hour, inclusive of 0.75 pharmacology hours. Presented by expert Mary W. Dunn, MSN, RN, OCN, NP-C from the University of North Carolina, this program targets oncology nurses, nurse navigators, advanced nursing providers, and nurses from other cancer-related subspecialties. It remains available until April 30, 2024, leaving ample time to gain this crucial knowledge. Primarily, this webcast zeroes in on bladder cancer (BC), a malignancy notorious for its high mortality rate, and renal cell carcinoma (RCC), a top-10 common cancer. Unfortunately, BC’s 5% survival rate for metastatic disease cases paints a grim picture. Luckily, hope emerges in the form of novel therapeutic agents for advanced, recurrent, and metastatic BC and RCC. Next, the program navigates through the pathogenesis of these cancers. Equipped with this knowledge, healthcare providers can better understand the intricacies of disease progression. As the treatment landscape rapidly evolves, so does the complexity in selection, sequencing, and adverse event (AE) management. Thus, the webcast outlines how to […]

Demonstrating compelling efficacy in the EV-103 trial, the combination of enfortumab vedotin-ejfv and pembrolizumab emerges as a promising treatment for patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based chemotherapy. The recent approval of enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are ineligible for cisplatin-based chemotherapy was substantiated by compelling results from the multi-cohort Phase 1b/2 EV-103 trial. In the dose escalation cohort and cohort A of the trial, patients received this innovative combination therapy. In cohort K, patients were randomized to receive either the combination or enfortumab vedotin-ejfv monotherapy. The main efficacy outcome measures were the objective response rate (ORR) and duration of response (DOR), with the ORR reaching 68% (95% CI, 58.7-76.0) among the 121 patients who received the combination therapy. Moreover, the median DOR was reported as 22.1 months for the dose escalation and cohort A. Nevertheless, patients did report a range of adverse reactions, most commonly increased glucose, increased aspartate aminotransferase, rash, and decreased hemoglobin, among others. The approval of this therapy is dependent on the validation and depiction of clinical benefits from the ongoing Phase 3 EV-302 confirmatory trial. Given the promising ORR […]

The decision was based on the findings of the open-label, multi-cohort, multicenter, phase 1b/2 clinical trial EV-103/KEYNOTE-869. Patients who participated in the study and were included in the current analysis had locally advanced or metastatic disease, were ineligible for cisplatin-containing chemotherapy, and had not previously received systemic therapy. The primary efficacy outcome measures for the study were the objective response rate (ORR) and duration of response (DoR), which were determined by an independent central review using RECIST v1.1. The ORR for the 121 patients treated with the combination was 68%, with 12% having a complete response. The median DoR for dose escalation was 22 months for two cohorts but not for a third.